VRX Stock Ownership Activity

VALEANT PHARMACEUTICALS INTL 13F holders

No value investing guru has made any change to the VALEANT PHARMACEUTICALS INTL (VRX) position according to the gurus' latest SEC quarterly report(s).

Which gurus or hedge funds are buying VRX now?

According to the latest SEC filing(s) VALEANT PHARMACEUTICALS INTL (VRX) has not been purchased by any super investor.

To see more about who is investing in VALEANT PHARMACEUTICALS INTL (VRX), please go to the VRX ownership page.

2018 Q3 (3 results)
Jeffrey Ubben
-100.00%
-18,033,149
-4.12%
0.00%
Francis Chou
-100.00%
-1,648,992
-13.87%
0.00%
Bill Miller
-100.00%
-4,999,064
-3.79%
0.00%
AVG reported price*: $23.24
2018 Q2 (2 results)
Jeffrey Ubben
+0.12%
+21,612
+0.00%
0.00%
Bill Miller
-7.67%
-415,000
-0.36%
0.00%
AVG reported price*: $23.24
2018 Q1 (3 results)
Jeffrey Ubben
+0.01%
+1,510
+0.00%
2.87%
Francis Chou
+1,006.77%
+997,500
+10.27%
7.51%
Bill Miller
-19.77%
-913,855
-0.91%
2.53%
AVG reported price*: $15.92
2017 Q4 (2 results)
Francis Chou
-95.12%
-2,280,308
-26.36%
1.06%
Bill Miller
-1.96%
-134,754
-0.12%
6.07%
AVG reported price*: $20.78
2017 Q3 (3 results)
Ravenel Boykin Curry IV
-100.00%
-15,918
-0.00%
0.00%
Jeffrey Ubben
+0.07%
+7,425
+0.00%
1.50%
Bill Miller
-1.83%
-96,101
-0.08%
3.40%
AVG reported price*: $14.33
2017 Q2 (2 results)
Francis Chou
+29.74%
+700,000
+3.81%
16.64%
Bill Miller
+22.88%
+1,305,373
+1.03%
5.51%
AVG reported price*: $17.33
2017 Q1 (4 results)
Jeffrey Ubben
+20.03%
+3,002,963
+0.28%
1.66%
Francis Chou
+20.04%
+393,000
+1.46%
8.76%
Bill Miller
+17.51%
+850,175
+0.49%
3.26%
Bill Ackman
-100.00%
-18,114,432
-4.41%
0.00%
AVG reported price*: $11.03
2016 Q4 (4 results)
Ravenel Boykin Curry IV
-45.40%
-7,080
-0.00%
0.00%
Francis Chou
+35.53%
+408,630
+2.45%
7.43%
Bill Miller
+111.90%
+2,564,100
+1.98%
3.75%
Bill Ackman
-16.10%
-3,476,690
-0.85%
0.00%
AVG reported price*: $14.52
2016 Q3 (2 results)
Ravenel Boykin Curry IV
-6.72%
-2,100
-0.00%
0.00%
Bill Miller
+14.21%
+285,100
+0.40%
3.21%
AVG reported price*: $24.56
2016 Q2 (5 results)
Ravenel Boykin Curry IV
-99.47%
-5,867,292
-0.51%
0.00%
Glenn Greenberg
-100.00%
-2,034,281
-2.99%
0.00%
Francis Chou
+48.11%
+470,000
+3.68%
11.33%
David Tepper
-100.00%
-902,475
-0.65%
0.00%
Bill Miller
+26.90%
+425,350
+0.55%
2.61%
AVG reported price*: $20.14
2016 Q1 (10 results)
Stephen Mandel
-100.00%
-4,925,571
-3.02%
0.00%
Ravenel Boykin Curry IV
-16.14%
-1,135,554
-0.12%
0.65%
Ole Andreas Halvorsen
-100.00%
-7,793,397
-3.49%
0.00%
James Crichton
-100.00%
-800,000
-2.34%
0.00%
Glenn Greenberg
-67.46%
-4,218,050
-5.41%
0.00%
Francois Rochon
-100.00%
-127,735
-2.55%
0.00%
Francis Chou
buy
+976,843
+6.19%
6.19%
David Tepper
buy
+902,475
+0.50%
0.00%
Bill Miller
buy
+885,332
+2.06%
1.16%
Bill Ackman
+30.14%
+5,000,000
+1.49%
6.41%
AVG reported price*: $26.31
2015 Q4 (9 results)
Stephen Mandel
-21.88%
-1,379,632
-0.74%
0.00%
Ravenel Boykin Curry IV
+108.43%
+2,268,814
+1.52%
1.81%
Ole Andreas Halvorsen
+56.08%
+2,800,044
+1.07%
0.00%
Nathaniel Simons
-100.00%
-1,344,024
-6.56%
0.00%
Leon Cooperman
-100.00%
-484,915
-1.89%
0.00%
James Crichton
buy
+800,000
+2.55%
0.00%
Glenn Greenberg
+12.09%
+370,941
+2.72%
13.87%
Francois Rochon
+1.89%
+2,374
+0.05%
0.00%
Bill Ackman
-14.80%
-2,882,811
-2.35%
13.54%
AVG reported price*: $101.65
49 of 116

Shares, change to shares, sold shares - split-adjusted.

Reported price - this doesn't represent the actual buy or sell price.
It is the split-adjusted price of the security as of the last day of the reported period.

Value or Price - If the security is completely sold out, we show the reported value (or price) prior to the actual period.